SERB Pharmaceuticals
Highly Engaged Employees
Manufacturing · France · 201-500 Employees
View Company Info for Free
Overview
Headquarters
32 Rue De Monceau, Paris, Ile-de-France,...Phone Number
+33 173032000Website
www.serb.comRevenue
$168.8 MillionIndustry
About SERB Pharmaceuticals
SERB Pharmaceuticals Org Chart
Is SERB Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if SERB Pharmaceuticals had a recent Job posting/layoffs
SERB Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if SERB Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at SERB Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once SERB Pharmaceuticals has new funding data
Earning: See what the market has to say on SERB Pharmaceuticals recently announced quarterly report
Check if SERB Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when SERB Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined SERB Pharmaceuticals as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
SERB Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SERB Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SERB Pharmaceuticals.
SERB Pharmaceuticals Tech Stack
A closer look at the technologies used by SERB Pharmaceuticals
Most Recent Scoops
SERB Pharmaceuticals News & Media
SERB signs agreement to acquire Idefirix rights for $133.6m
Hansa will receive €110m upfront and a further €5m once the European Medicines Agency accepts Idefirix’s full approval filing.SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
SERB Pharmaceuticals to acquire development and commercialisation rights to Idefirix® (imlifidase) in Europe and MENA from Hansa Biopharma for €115 millionSERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the US
SERB Pharmaceuticals announced that ThyroSafe potassium iodide tablets are now commercially available in a 130 mg dose.Vignesh Rajah named SERB Pharmaceuticals' CMO | The Pharmaletter
Specialty pharma company SERB Pharmaceuticals has revealed the appointment of Vignesh Rajah as its chief medical officer (CMO).
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SERB Pharmaceuticals
SERB Pharmaceuticals is a company that operates in the Pharmaceuticals industry. It employs 500to999 people and has 100MMto250M of revenue. The company is headquartered in Paris, Ile-de-France, France.... Read More